In light of the Brexit vote, we reflect upon the implications for the NHS and the wider healthcare industry. We take a pragmatic approach to how the referendum result will affect staffing, recruitment, clinical trials, drug pricing and small company grant funding in the coming months and years.

30 Aug 2016
Rude Health - Life Sciences quarterly sector note
RUA Life Sciences Plc (RUA:LON), 12.5 | Bioventix Plc (BVXP:LON), 2,850 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.2 | SDI Group plc (SDI:LON), 55.5 | Synairgen plc (SNG:LON), 0.8 | Tristel Plc (TSTL:LON), 325

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Rude Health - Life Sciences quarterly sector note
RUA Life Sciences Plc (RUA:LON), 12.5 | Bioventix Plc (BVXP:LON), 2,850 | Cambridge Nutritional Sciences PLC (CNSL:LON), 3.2 | SDI Group plc (SDI:LON), 55.5 | Synairgen plc (SNG:LON), 0.8 | Tristel Plc (TSTL:LON), 325
- Published:
30 Aug 2016 -
Author:
Mark Brewer -
Pages:
28 -
In light of the Brexit vote, we reflect upon the implications for the NHS and the wider healthcare industry. We take a pragmatic approach to how the referendum result will affect staffing, recruitment, clinical trials, drug pricing and small company grant funding in the coming months and years.